LEADERSHIP, PARTNERS & INVESTORS
A WORLD CLASS LEADERSHIP TEAM
InnerPulse's corporate officers and board of directors bring a breadth and
depth of experience in technology research & development, sales, marketing, business operations,
and other areas of management with medical device industry leaders. They have been equally
successful in startup and corporate environments.
LEARN MORE>THE EXPERTISE TO ASSURE SUCCESS
Our Technology Partners
To address the challenge of enabling our percutaneous implantable defibrillator, the PICD™,
to deliver the same operational performance as its larger, conventional counterparts,
InnerPulse has forged exclusive development agreements with, to date, three technology leaders:
- Greatbatch, Inc. (NYSE: GB)-a leading developer and manufacturer of critical components
such as batteries and capacitors used in implantable medical devices and other technically
demanding applications. For InnerPulse, the company is developing an exclusive new generation
of components based on its proprietary technology. For more information, visit
www.greatbatch.com.
- AMI Semiconductor, Inc. (NASDAQ: AMIS)-a leading developer of low-power, mixed-signal, and wireless implantable
medical-semiconductor solutions. The company's ASIC technology will enable InnerPulse's PICD™ to provide life-saving
defibrillator technology will ultra-low-power solutions. For more information, visit
www.amis.com.
- Enpath Medical (NASDAQ: NPTH)-a leading developer and manufacturer of stimulation leads and therapy
delivery systems for Cardiac Rhythm Management (CRM), Neuromodulation and Interventional Radiology markets.
For more information, visit www.enpathmed.com.
Our Investors
To date, InnerPulse has raised $85.2 million through three rounds of private financings. Investors include:
- Delphi Ventures—a private venture-capital firm focusing on early-stage U.S. medical device and
biotechnology investments. Founded in 1988, the company has approximately $600 million under management
and invested in more than 125 healthcare companies. For more information, visit
www.delphiventures.com.
- Frazier Healthcare Ventures—a venture-capital firm supporting emerging growth companies across the
healthcare industry at all stages of development, from incubation to late stage. With more than
$1 billion under management, the firm takes an active role in its investments and has one of the
largest healthcare investment teams in the venture-capital community. For more information,
visit www.frazierco.com.
- Johnson & Johnson Development Corporation (JJDC)—the venture capital subsidiary of Johnson & Johnson.
JJDC makes private equity investments in venture-funded healthcare companies. Portfolio companies include
those in the fields of pharmaceuticals, biotechnology, medical devices, diagnostics, and consumer products.
Organized in 1973, JJDC also leads and manages internal investments in selected promising technologies.
For more information, visit www.jjdevcorp.com.
-
Medtronic, Inc.—the world leader in medical technology providing lifelong solutions for people with chronic disease. Medtronic offers products, therapies and services that enhance or extend the lives of people worldwide. Each year, 5 million patients benefit from Medtronic's technology, used to treat conditions such as diabetes, heart disease, neurological disorders, and vascular illnesses.
For more information visit www.medtronic.com
- Boston Scientific Corporation - Boston Scientific's mission is to improve the quality of patient care and the productivity of health care delivery through the development and advocacy of less-invasive medical devices and procedures. This is accomplished through the continuing refinement of existing products and procedures and the investigation and development of new technologies that can reduce risk, trauma, cost, procedure time and the need for aftercare.
For more information, visit www.bostonscientific.com
|
